TALECRIS VISION
CORPORATE SITES
Talecris Canada
Talecris Europe
Talecris United States
View All
PRODUCT SITES
Alpha-1 Antitrypsin Deficiency
(Prolastin/Prolastina)
Immune Globulin Intravenous
Therapy
(IGIV) (Gamunex)
Antihemophilic Factor VIII
(Koāte-DVI)
Antithrombin III (AT III)
(Thrombate)
Human Albumin Products
(Plasbumin / Plasmanate)
Hyperimmune Globulin Therapy
(Hypermunes)
View All
PROGRAMS & SERVICES
Gamunex Connexions
Gamunex Direct
Prolastin Direct
Contract Manufacturing Services
Talecris Plasma Resources
View All
CONTACT TALECRIS
Home
About Talecris
Therapeutic Areas
Research & Development
Donor to Patient
Business Development
Investor Relations
Media Center
Media Center Overview
Press Releases
Press Releases Archive
News Features
The History of Talecris
Talecris Leadership
Talecris Media Contact Information
Media Center Overview
Press Releases
Subscribe to the Talecris Press Release RSS feed (W3C validated, Requires IE7 or higher)
August 09, 2010
Talecris Biotherapeutics and Grifols Receive FTC Request for Additional Information Regarding Proposed Merger
July 14, 2010
Talecris Biotherapeutics Announces Premerger HSR Filing
July 08, 2010
Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
June 25, 2010
Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association
June 18, 2010
Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
See how Talecris is being
recognized for innovation and commitment
.
Contact Talecris
Glossary
Site Map
General Conditions of Use
Privacy Statement
California Compliance
© 2009 Talecris Biotherapeutics
